Conjunctivitis Treatment Market Expected to Reach $6.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Conjunctivitis Treatment Market," The conjunctivitis treatment market was valued at $4.2 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 3.8% from 2022 to 2031.

Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the “bulbar conjunctiva” which covers the globe and the “tarsal conjunctiva” which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.

Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global Conjunctivitis Treatment Industry. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the gConjunctivitis Treatment Market growth. Further, different technologies employed in the development of effective treatment boost the growth of Conjunctivitis Treatment Market size.

However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is classified into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. Based on drug class, it is categorized into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.

By region, North America accounted for the largest market share in the Conjunctivitis Treatment Market share in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure. However, Asia-Pacific witnessed the highest growth rate for the conjunctivitis treatment market and is expected to continue this Conjunctivitis Treatment Market trends throughout the forecast period, which is attributed to presence of high population base and increase in healthcare expenditure.

The report provides a comprehensive analysis of the key players that operate in the global conjunctivitis treatment market. The key companies profiled in the report include AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.

Key findings of the study

• On the basis of disease type, the allergic conjunctivitis segment held 4.3% share in the global market in 2021.
• On the basis of drug class, the anti-allergic segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• On the basis of distribution channel, the hospital pharmacy segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• Region wise, North-America is expected to experience the highest market share during the forecast period.